A new way of working has been agreed between the Department of Health and the Association of the British Pharmaceutical Industry which will lead to quicker starting of clinical trials. The model clinical trials agreement should speed up the research overall and lead to earlier availability of new products for the NHS where the trials are successful.
Welcoming this development, Health Minister, Lord Philip Hunt said: "The NHS has always been a good place for pharmaceutical companies to do clinical research. This new agreement is good news for the pharmaceutical industry, clinical researchers and patients. It means that trials start earlier, more patients are recruited into trials, and the NHS and patients will get quicker access to new drugs."
Dr Richard Tiner, Director of Medicine at the ABPI said: "This is a major step towards keeping clinical trials work in the UK - something that is very important, given the pivotal part that clinical trials play in the development of new medicines. The ABPI regards the production of this document as an excellent example of the way in which industry and Government can work together to ensure that Britain remains competitive with other countries."
Discussions on this agreement were signalled in the Clinical Research Report published last March, which provided an update on actions since the main report of the Pharmaceutical Industry Competitiveness Task Force. The ABPI is encouraging its members to adopt the agreement in planning and arranging clinical trials in hospitals, and the Department will likewise promote it to NHS trusts.
For further information, please contact: ABPI Press Office 020 7747 1410